Afinitor/Aromasin combo disappoints in breast cancer trial PharmaTimes Eagerly-awaited results from the BOLERO-2 trial looking at the mTOR inhibitor Afinitor (everolimus) plus the aromatase inhibitor Aromasin (exemestane) were presented at the European Breast Cancer Conference in Glasgow and proved disappointing. In the ... |
